WaveForm Technologies, Inc Awarded CE Mark Approval for Their CGM System
Novel Continuous Glucose Monitoring System Offers 14 Day Wear, Simple, Virtually Pain-Free Insertion and Minute-to-Minute Glucose Readings Transmitted Directly to…
AgaMatrix, Inc. and WaveForm Technologies, Inc. Complete $56 Million Capital Raise
SALEM, NH and WILSONVILLE, OR, July 3, 2019 – AgaMatrix, Inc. (“AgaMatrix”) and WaveForm Technologies, Inc. (“WaveForm”), wholly owned subsidiaries…
WaveForm Technologies and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of CGM Solutions
Wilsonville, OR and Florence, Italy April 5, 2019 – WaveForm Technologies, Inc. a wholly owned subsidiary of WaveForm Diabetes (formerly…
WaveForm Technologies Receives Favorable Decision on Critical Glucose Monitoring Patents
The US Patent Office Patent Trial and Appeal Board recently ruled to uphold the validity of WaveForm Technologies, Inc. patents…
WaveForm Technologies Announces Clinical Trial Results For Its Continuous Glucose Monitoring System
WILSONVILLE, OR, Jan 11, 2018 – WaveForm Technologies Inc., a developer of novel products for diabetes care, today announced it…
AgaMatrix Completes $32 Million Financing Transaction With Prospect Capital
SALEM, NH, October 5, 2017 – AgaMatrix, Inc. (“AgaMatrix”), a wholly owned subsidiary of WaveForm Diabetes (formerly AgaMatrix Holdings, LLC),…